“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in GBP
Last close As at 25/03/2023
GBP0.10
▲ −0.55 (−5.09%)
Market capitalisation
GBP6m
ReNeuron Group is a UK biotech focused on the development of its stem cell-derived exosome drug delivery platform (CustomEx). It operates as a contract research and development organisation (CDRO) and its established partners are progressing the preclinical development of exosome-based therapeutics utilising its CustomEx technology.
Drug delivery remains a major challenge in both central nervous system (CNS) and cell and gene drug development, and we view these as key markets for ReNeuron to target with its exosome drug delivery platform. Additionally, ReNeuron’s diversification in exosome producing stem cell lines and ability to produce exosomes with enhanced natural tissue targeting affinity, particularly neural stem cell lines to target CNS indications, may offer market differentiation against single cell line competitors.
Managing Director - Head of Content, Healthcare
Ian Ross
Chairman
John Hawkins
CFO
John Sinden
Chief Scientific Officer
Forecast net cash (£m)
11
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (4.7) | (16.3) | (61.3) |
| Relative | (5.0) | (20.8) | (65.5) |
| 52 week high/low | 41.0p/8.8p |
ReNeuron Group is a UK biotech focused on the development of its stem cell-derived exosome drug delivery platform (CustomEx). The company operates as a contract research and development organisation (CRDO) and has established seven discovery stage collaborations with pharma, biotech and academic institutions, through which its proprietary CustomEx exosome platform is being investigated for application in targeted drug delivery. ReNeuron’s exosomes have shown encouraging preclinical proof-of-concept data to deliver complex therapeutic payloads with high tissue specificity.
| Y/E Mar | Revenue (£m) | EBITDA (£m) | PBT (£m) | EPS (fd) (p) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 0.3 | N/A | (13.4) | (29.00) | N/A | N/A |
| 2022A | 0.4 | N/A | (11.1) | (17.01) | N/A | N/A |
| 2023E | 0.8 | N/A | (8.9) | (13.27) | N/A | N/A |
| 2024E | 0.9 | N/A | (9.6) | (14.37) | N/A | N/A |
Managing Director - Head of Content, Healthcare
Get access to the very latest content matched to your personal investment style.
